[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344495-105":59,"doc-detail-344495-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","field-cancerization-in-urothelial-carcinoma-molecular-alterations-and-clinical-implications","Field cancerization in urothelial carcinoma - molecular alterations and clinical implications","","Urothelial carcinoma (UC) is a common urinary tract malignancy marked by frequent recurrence, especially in non-muscle-invasive disease. Traditional explanations include residual tumor cells, intraluminal seeding, or expansion of disseminated clones. Molecular evidence shows that urothelium appearing normal on routine histology can already contain cancer-related alterations, supporting field cancerization. This review synthesizes sequencing, methylation, spatial mapping, and multi-omics findings, linking field-wide somatic, epigenetic, metabolic, and microenvironmental remodeling to clonal expansion, multifocal development, and post-treatment recurrence.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/field-cancerization-in-urothelial-carcinoma-molecular-alterations-and-clinical-implications/344495/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/field-cancerization-in-urothelial-carcinoma-molecular-alterations-and-clinical-implications/344495.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is field cancerization in urothelial carcinoma?","Question",{"text":113,"@type":114},"Field cancerization refers to molecular alterations accumulating in urothelial tissue after prolonged exposure to carcinogens and chronic insults, occurring before visible morphological changes develop.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why does recurrence remain common in non-muscle-invasive bladder cancer?",{"text":118,"@type":114},"Recurrence persists because biologically altered urothelial fields can support clonal expansion, multifocal tumor development, and later recurrence after treatment.",{"name":120,"@type":111,"acceptedAnswer":121},"How can molecular analysis of histologically normal urothelium help clinically?",{"text":122,"@type":114},"Characterizing apparently uninvolved urothelium may refine risk assessment beyond conventional histopathology and guide strategies such as perioperative urinary tumor DNA testing.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344495,1790167828,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Journal of Cancer 2026, Vol. 17 1491  \nIvyspring  \nInternational Publisher  \nJournal of Cancer  \n2026; 17(8): 1491-1503. doi: 10.7150/jca.125266  \nReview  \nField cancerization in urothelial carcinoma: molecular alterations and clinical implications  \nXinni Ye\\#, Junhao Chen\\#, Hongqiong Li\\#, Haonan Dong\\#, Tianjiao Luo, Peng Chen, Haifeng Wang􀀍 and Shi Fu􀀍  \nDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, Yunnan, 650106, China.  \n\\# Contributed equally.  \n􀀍 Corresponding authors: Haifeng Wang ([wanghaifeng@kmmu.edu.cn](wanghaifeng@kmmu.edu.cn)) and Shi Fu ([fushi@kmmu.edu.cn](fushi@kmmu.edu.cn))  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.09.16; Accepted: 2026.07. 31; Published: 2026.08.10  \nAbstract  \nUrothelial carcinoma (UC) is a common malignancy of the urinary tract and is characterized by frequent recurrence, particularly in patients with non-muscle-invasive disease. Recurrence has traditionally been explained by residual tumor cells, intraluminal seeding, or the outgrowth of disseminated clones. However, molecular studies have shown that urothelium that appears normal under routine histological examination may already harbor cancer-related alterations. These findings support the concept of field cancerization, whereby prolonged exposure to carcinogens, chronic inflammation, and other injurious stimuli produces a biologically altered urothelial field before overt malignancy becomes visible.  \nIn this review, we searched PubMed and Web of Science for relevant studies published up to January 2026. We focused on investigations of peritumoral tissue or histologically normal-appearing urothelium that reported molecular abnormalities associated with UC development or recurrence. Available evidence from sequencing, methylation profiling, spatial mapping, and multi-omics studies indicates that field changes may involve somatic mutations, copy-number alterations, epigenetic dysregulation, metabolic reprogramming, and remodeling of the local immune and stromal microenvironment. These changes may create a permissive background for clonal expansion, multifocal tumor development, and recurrence after treatment.  \nAlthough the clinical definition and spatial extent of the urothelial field remain unsettled, molecular characterization of apparently uninvolved urothelium may help refine risk assessment beyond conventional histopathology. In particular, perioperative urinary tumor DNA testing may assist in identifying molecular residual disease and support more individualized surveillance or adjuvant treatment decisions.  \nKeywords: Urothelial carcinoma; Field cancerization; Peritumoral tissue; Microenvironment; Gene mutations  \n1. Introduction  \nUrothelial carcinoma (UC) arises from theurothelial lining of the renal pelvis, ureter, bladder, and urethra. Among these sites, bladder cancer (BC) accounts for more than 90% of UC cases, and approximately 75% of patients present with nonmuscle-invasive bladder cancer (NMIBC) at diagnosis [1] . Although cystoscopy, urine cytology, and molecular testing have improved clinical management, recurrence remains common, especially in NMIBC. A proportion of patients also experience disease progression, which creates a substantial longterm treatment and surveillance burden [2, 3] .  \nTraditionally, local recurrence has been explained by persistent tumor cells that remain after treatment or by implantation of exfoliated tumor cells within the urothelial tract. This interpretation is supported by studies showing shared genomic alterations among lesions detected at different times or locations, suggesting that they originated from a common ancestral clone [4] . On this basis, clinical asses","cbCaipeJ0ijrfsqd","https://ap.wps.com/l/cbCaipeJ0ijrfsqd","pdf",1239666,13,"English","# Abstract\n# 1. Introduction\n## Urothelial carcinoma origin and recurrence burden\n## Limitations of histopathology and evidence for field cancerization\n## Field cancerization concept and clinical implications","[{\"question\":\"What is field cancerization in urothelial carcinoma?\",\"answer\":\"Field cancerization refers to molecular alterations accumulating in urothelial tissue after prolonged exposure to carcinogens and chronic insults, occurring before visible morphological changes develop.\"},{\"question\":\"Why does recurrence remain common in non-muscle-invasive bladder cancer?\",\"answer\":\"Recurrence persists because biologically altered urothelial fields can support clonal expansion, multifocal tumor development, and later recurrence after treatment.\"},{\"question\":\"How can molecular analysis of histologically normal urothelium help clinically?\",\"answer\":\"Characterizing apparently uninvolved urothelium may refine risk assessment beyond conventional histopathology and guide strategies such as perioperative urinary tumor DNA testing.\"}]","Field cancerization in urothelial carcinoma - molecular alterations and clinical implications | PDF",1790054067,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e248251315e49bc6b88961ed72c238a0.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99d6f13b558de8362a333b828bc2b540.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02f7265d7d5c80fcdeaff4925ea0308b.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02e5670b785f021064216157e82fee0c.webp",980,1268]